// App-Quantinova.ai

PB2032 : MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Researchers

Presenter

  • Rafael Fonseca

Principal Investigators

  • Junya Kuroda

  • Tadao Ishida

  • Rakesh Popat

  • Jeffrey SY Huang

  • Anne Yver

  • Erik Vandendries

  • Mohamed Elmeliegy

  • Wei Dong Ma

  • Douglas W Sborov

Medical Centers

  • Pfizer Inc.,Paris,Frankreich

  • Pfizer Inc,La Jolla,Vereinigte Staaten

  • Pfizer Oncology, La Jolla, CA

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Pfizer Inc., New York, United States

  • Pfizer Inc,La Jolla,Stati Uniti

  • Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

  • Division of Hematology and Oncology,Kyoto Prefectural University of Medicine,Kyoto,Giappone

  • Pfizer Inc., Cambridge, MA

  • Division of Hematology,National Taiwan University Hospital,Taipei,台湾，China

  • Hematology and Oncology,Huntsman Cancer Institute,Salt Lake City,United States

  • Division of Hematology,National Taiwan University Hospital,Taipei,Taiwan, China

  • Division of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Pfizer Inc.,Paris,Франция

  • Japanese Red Cross Medical Center, Tokyo, Japan

  • Pfizer Inc,La Jolla,Estados Unidos

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Pfizer Inc,La Jolla,United States

  • Pfizer Inc,Cambridge,Verenigde Staten

  • Division of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Соединённое Королевство

  • Division of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

  • Division of Hematology,National Taiwan University Hospital,Taipei,Taiwan, China

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Epizyme, Inc.,Cambridge,Estados Unidos

  • Hematology and Oncology, Kyoto Prefectural University Of Medicine, Kyoto, Japan

  • Pfizer Inc,New York,États-unis

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Division of Hematology and Oncology,Kyoto Prefectural University of Medicine,Kyoto,Giappone

  • Pfizer Inc,La Jolla,États-unis

  • Pfizer Inc,Paris,França

  • Pfizer Inc.,Paris,Frankreich

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Pfizer Inc., Paris, France

  • Pfizer Inc,New York,Stati Uniti

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

  • Pfizer Inc.,Paris,Frankreich

  • Division of Hematology,National Taiwan University Hospital,Taipei,台湾，China

  • Pfizer Inc, New York/US

  • NIHR UCLH Clinical Research Facility,University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Division of Gastroenterology, National Taiwan University Hospital, Taipei, Taiwan

  • Pfizer Inc.,Cambridge,Stati Uniti

  • Pfizer Inc,New York,Verenigde Staten

  • Pfizer Inc,Cambridge,United States

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Division of Hematology,National Taiwan University Hospital,Taipei,台湾，China

  • Pfizer Inc., Paris, France

  • Pfizer Inc,Cambridge,Verenigde Staten

  • Pfizer Inc,New York,Verenigde Staten

  • Division of Hematology &amp

  • Hematologic Malignancies,Huntsman Cancer Institute,Salt Lake City,Stati Uniti

  • Pfizer Inc,New York,Estados Unidos

  • Pfizer Inc,La Jolla,Vereinigte Staaten

  • Pfizer Inc,Cambridge,États-unis

Locations

  • United States

  • Japan

  • United Kingdom

  • Taiwan

  • China

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Multiple Myeloma

  • Cytokine release syndrome

  • Primary plasma cell leukemia

  • POEMS syndrome

  • Skin carcinoma

  • Amyloid disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT05014412

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved